Rankings
▼
Calendar
SMMT Q4 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
SMMT
Summit Therapeutics Inc.
$12B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$705
-99.7% YoY
Gross Profit
-$595,000
-84397.2% margin
Operating Income
-$20M
-2879290.8% margin
Net Income
-$19M
-2727517.7% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
-99.7%
Cash Flow
Operating Cash Flow
$5M
Free Cash Flow
$6M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$664M
Total Liabilities
$538M
Stockholders' Equity
$127M
Cash & Equivalents
$349M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$705
$251,000
-99.7%
Gross Profit
-$595,000
$251,000
-337.1%
Operating Income
-$20M
-$26M
+22.1%
Net Income
-$19M
-$26M
+25.3%
Revenue Segments
License and Service
$4M
100%
← FY 2022
All Quarters
Q1 2023 →